3rd Circ. Won't Revive Cephalon Shareholder Case

Law360, New York (December 15, 2010, 1:37 PM EST) -- A federal appeals court has refused to revive a Cephalon Inc. shareholder's suit accusing the company's board and CEO of failing to properly oversee sales and promotions practices for the drugs Provigil, Actiq and Gabitril.

In a nonprecedential opinion, the U.S. Court of Appeals for the Third Circuit ruled on Tuesday that a lower court had correctly tossed Cephalon stockholder Jerald King's suit because he failed to plead that a presuit demand on the board would have been futile.

King filed his shareholder derivative suit in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.